Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1

The purpose of this study is to look at how feasible it is to incorporate a state-of-the-art smoking cessation treatment program into community substance abuse treatment programs and its impact on substance abuse and cigarette smoking.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tobacco Use Disorder Chemically-Induced Disorders Mental Disorders Substance-Related Disorders

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Matrix Institute on Addictions, Los Angeles, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient is alcohol or drug dependent, in Outpatient Drug-Free or Opiate Substitute program and is interested in quitting smoking

Exclusion criteria

Patient is psychotic
Use of smokeless tobacco
Use of other smoking cessasation product
Pregnancy
Patient has hyper-tension, heart problems, or skin condition

Treatment and study plan

nicotine transdermal system

Drug

Primary outcomes

Drug use
Smoking Cessation

Sponsors and collaborators

Lead sponsor

New York University

Other

Registry information

Official study title

Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy

Important dates

Study start: 2003
Primary completion: 2004
Study completion: 2004
First posted: Aug 13, 2003
Registry last updated: Jan 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed